Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06259110
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-14
First Post:
2024-01-22
Brief Title:
Community-Acquired Pneumonia Diagnosis Through Integrating Novel Microbiological Techniques
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Revolutionizing Community-Acquired Pneumonia Diagnosis Through Integrating Novel Microbiological Techniques for Enhanced Precision
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate novel microbiological techniques for enhanced Pathogen Identification assess the speed and efficiency of the integrated approach in providing timely diagnostic results aiming to reduce the turnaround time for CAP diagnosis and subsequently improve patient outcomes and evaluate the clinical impact of enhanced precision in CAP diagnosis on treatment decisions including the potential for targeted and more effective antimicrobial therapy based on accurate pathogen identification
Detailed Description:
Community-acquired pneumonia CAP is the term used to describe an acute infection of the lungs that develops outside the hospital setting in a patient who has not been recently hospitalized
Community-acquired pneumonia CAP is one of the most common infectious diseases and is a significant cause of mortality and morbidity globally despite preventative measures aimed at combating CAP
These measures include pneumococcal vaccination of at-risk groups yearly vaccinations for seasonal influenza viruses and since 2021 SARS-CoV-2 vaccination
Understanding the etiology of CAP is crucial for accurate empirical antibiotic treatment updating treatment guidelines and future vaccine cost-benefit analyses Currently microbiological testing for CAP patients does not identify the etiology of most cases
In contrast molecular biology techniques are rapid and sensitive for the diagnosis of pathogens Furthermore a multitude of nascent technologies including multiplex real-time PCR that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample and microarray methodologies have become accessible for employment in clinical settings
Improved diagnostics may change the management of CAP infections prompt identification of the appropriate organism would allow antibiotic de-escalation which would decrease cost adverse drug effects and antibiotic resistance pressure These clinical interventions potentially translate to a reduced length of stay and financial savings for the patient as well as an improved therapeutic outcome
Community-acquired pneumonia CAP is one of the most common infectious diseases and is a significant cause of mortality and morbidity globally despite preventative measures aimed at combating CAP
These measures include pneumococcal vaccination of at-risk groups yearly vaccinations for seasonal influenza viruses and since 2021 SARS-CoV-2 vaccination
Understanding the etiology of CAP is crucial for accurate empirical antibiotic treatment updating treatment guidelines and future vaccine cost-benefit analyses Currently microbiological testing for CAP patients does not identify the etiology of most cases
In contrast molecular biology techniques are rapid and sensitive for the diagnosis of pathogens Furthermore a multitude of nascent technologies including multiplex real-time PCR that detect multiple respiratory pathogens including both bacteria and viruses from a single respiratory tract sample and microarray methodologies have become accessible for employment in clinical settings
Improved diagnostics may change the management of CAP infections prompt identification of the appropriate organism would allow antibiotic de-escalation which would decrease cost adverse drug effects and antibiotic resistance pressure These clinical interventions potentially translate to a reduced length of stay and financial savings for the patient as well as an improved therapeutic outcome
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None